Iovance Biotherapeutics Targets 2027 Lung Cancer Filing as AMTAGVI Sales Climb
Iovance Biotherapeutics (IOVA) reported updated clinical data for its lung cancer treatment, with a 25% response rate in 69 patients. The company plans to file for approval in 2027 and start a first-line lung study. Safety improvements were noted after regimen changes. IOVA also plans studies in melanoma and sarcoma. The company expects long-term gross margin improvement and has $382M in cash.



